Generic Kapspargo Sprinkle Availability
Last updated on Apr 10, 2025.
Kapspargo Sprinkle is a brand name of metoprolol, approved by the FDA in the following formulation(s):
KAPSPARGO SPRINKLE (metoprolol succinate - capsule, extended release;oral)
-
Manufacturer: SPIL
Approval date: January 26, 2018
Strength(s): EQ 25MG TARTRATE [RLD], EQ 50MG TARTRATE [RLD], EQ 100MG TARTRATE [RLD], EQ 200MG TARTRATE [RLD]
Is there a generic version of Kapspargo Sprinkle available?
No. There is currently no therapeutically equivalent version of Kapspargo Sprinkle available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Kapspargo Sprinkle. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Capsule dosage form of metoprolol succinate
Patent 9,504,655
Issued: November 29, 2016
Inventor(s): Vats Sandeep Kumar & Mondal Balaram & Ramaraju Kalaiselvan & Singh Romi Barat
Assignee(s): SUN PHARMACEUTICAL INDUSTRIES LIMITEDThe present invention provides an extended-release capsule dosage form of metoprolol succinate in the form of coated discrete units and processes for their preparation.
Patent expiration dates:
- July 9, 2035✓
- July 9, 2035
-
Capsule dosage form of metoprolol succinate
Patent 9,700,530
Issued: July 11, 2017
Inventor(s): Vats Sandeep Kumar & Mondal Balaram & Ramaraju Kalaiselvan & Singh Romi Barat
Assignee(s): SUN PHARMACEUTICAL INDUSTRIES LIMITEDThis disclosure provides an extended-release capsule dosage form of metoprolol succinate in the form of coated discrete units, wherein said capsule dosage form is bioequivalent to the marketed Toprol-XL® tablet. The extended-release capsule dosage form comprising coated discrete units can be sprinkled onto food to ease administration to patients who have difficulty swallowing tablets or capsules.
Patent expiration dates:
- July 9, 2035✓
- July 9, 2035
More about Kapspargo Sprinkle (metoprolol)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy or Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
